Psychiatric Neurobiology and Bipolar Disorder Program, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany.
Department of Biological and Clinical Psychology, University of Greifswald, Greifswald, Germany.
Mol Psychiatry. 2014 Jan;19(1):122-8. doi: 10.1038/mp.2012.172. Epub 2013 Jan 15.
Panic disorder with agoraphobia (PD/AG) is a prevalent mental disorder featuring a substantial complex genetic component. At present, only a few established risk genes exist. Among these, the gene encoding monoamine oxidase A (MAOA) is noteworthy given that genetic variation has been demonstrated to influence gene expression and monoamine levels. Long alleles of the MAOA-uVNTR promoter polymorphism are associated with PD/AG and correspond with increased enzyme activity. Here, we have thus investigated the impact of MAOA-uVNTR on therapy response, behavioral avoidance and brain activity in fear conditioning in a large controlled and randomized multicenter study on cognitive behavioral therapy (CBT) in PD/AG. The study consisted of 369 PD/AG patients, and genetic information was available for 283 patients. Carriers of the risk allele had significantly worse outcome as measured by the Hamilton Anxiety scale (46% responders vs 67%, P=0.017). This was accompanied by elevated heart rate and increased fear during an anxiety-provoking situation, that is, the behavioral avoidance task. All but one panic attack that happened during this task occurred in risk allele carriers and, furthermore, risk allele carriers did not habituate to the situation during repetitive exposure. Finally, functional neuroimaging during a classical fear conditioning paradigm evidenced that the protective allele is associated with increased activation of the anterior cingulate cortex upon presentation of the CS+ during acquisition of fear. Further differentiation between high- and low-risk subjects after treatment was observed in the inferior parietal lobes, suggesting differential brain activation patterns upon CBT. Taken together, we established that a genetic risk factor for PD/AG is associated with worse response to CBT and identify potential underlying neural mechanisms. These findings might govern how psychotherapy can include genetic information to tailor individualized treatment approaches.
惊恐障碍伴广场恐惧症(PD/AG)是一种常见的精神障碍,具有重要的复杂遗传成分。目前,只有少数已确定的风险基因存在。在这些基因中,编码单胺氧化酶 A(MAOA)的基因值得注意,因为遗传变异已被证明会影响基因表达和单胺水平。MAOA-uVNTR 启动子多态性的长等位基因与 PD/AG 相关,并且与增加的酶活性相对应。在这里,我们在惊恐障碍的认知行为治疗(CBT)的一项大型对照和随机多中心研究中,调查了 MAOA-uVNTR 对治疗反应、行为回避和恐惧条件反射中的大脑活动的影响。该研究包括 369 名 PD/AG 患者,其中 283 名患者有遗传信息。风险等位基因携带者的汉密尔顿焦虑量表(Hamilton Anxiety Scale)测量结果明显较差(46%的应答者与 67%的应答者相比,P=0.017)。这伴随着在引起焦虑的情况下心率升高和恐惧增加,即行为回避任务。在该任务期间发生的除一次惊恐发作外,均发生在风险等位基因携带者中,此外,风险等位基因携带者在重复暴露期间不会对该情况产生习惯化。最后,在经典的恐惧条件反射范式的功能神经影像学研究中,发现保护性等位基因与在获得恐惧时 CS+呈现时前扣带回皮层的激活增加有关。在治疗后对高风险和低风险受试者进行进一步区分时,观察到下顶叶的差异激活,表明在 CBT 后存在不同的大脑激活模式。总之,我们确定了惊恐障碍的一个遗传风险因素与对 CBT 的反应较差有关,并确定了潜在的神经机制。这些发现可能指导心理治疗如何纳入遗传信息以定制个体化的治疗方法。